Floatz logo

Sargramostim

Locally Advanced Pancreatic Adenocarcinoma

Barbara Ann Karmanos Cancer Instituteprotein_peptidePhase 1/2Active
B
59/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
52/ 100
Competitive Position
81/ 100

Competitive context

25 Active assets in the Locally Advanced Pancreatic Adenocarcinoma cohort.

Asset / SponsorPhaseRating
PANITUMUMAB
SWOG Cancer Research Network
Phase 3B
Gdc-0449
OHSU Knight Cancer Institute
Phase 2B
Inno-206
OHSU Knight Cancer Institute
Phase 2B
Regorafenib
OHSU Knight Cancer Institute
Phase 2B
Kinisoquin™
Quercis Pharma AG
Phase 3B

View all 50 →

Same molecule, other indications

Sargramostim is also rated in:

cancer of unknown primary siteDormant
BBB
Indicative ·
72 / 100
View asset →
melanomaDormant
BBB
Indicative ·
72 / 100
View asset →
chronic myeloid leukemiaDormant
BBB
Indicative ·
72 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →